6533b82efe1ef96bd1293ad4

RESEARCH PRODUCT

530MO Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ)

S.r. ChandanaMatthew D. GalskyAndrés CervantesLisa G. HorvathMelissa Lynne JohnsonEmiliano CalvoHaeseong ParkLinda MileshkinRuth PlummerJ. EvansK. QuR.j. PelhamSiquing FuM. BarveV. MorenoA. StradellaSwati GoelL. Fariñas-madridAmy PrawiraTobias Arkenau

subject

Oncologymedicine.medical_specialtyTemozolomidebusiness.industryLow doseLocally advancedHematologyPARP1OncologyInternal medicinemedicineBiomarker (medicine)businessmedicine.drughttps://doi.org/10.1016/j.annonc.2020.08.644